Michel Guinot

Cortisol and GH: odd and controversial ideas.

Activation of the hypothalamo-pituitary-adrenal (HPA) axis and of the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis represents a physiological response to the energetic, metabolic, vascular, and sometimes neurophysiologic or psychological needs of exercise. Long-lasting increased and (or) decreased secretion of cortisol (the end-product of the HPA axis) or of GH is detrimental to health. This suggests that the activity of these hormonal axes is finely tuned toward homeostasia, tolerating limited prolonged homeostatic disruption. However, the relationships between exercise training and cortisol and GH secretion are full of odd and controversial ideas. In this review, the relationships between HPA axis adaptation to exercise training or disadaptation with overtraining will be discussed, with an emphasis on the limitation on the current measures used to profile hormonal activity. Knowledge of these relationships between cortisol and GH responses to exercise is an important tool to fight against doping with glucocorticoids and GH, and their health-damaging consequences.

Oxidative stress and metabolism at rest and during exercise in persons with Down syndrome.

Background Down syndrome (DS) is a risk factor for metabolic syndrome and cardiovascular disease. The greater oxidative stress described in DS can increase this risk owing to its potential deleterious effects on insulin sensitivity. We hypothesized that metabolic syndrome or its markers, at rest and during exercise, are more pronounced in young adults with DS. Design The study design is that of a controlled study. Methods Thirteen physically active young adults with DS, after overnight polysomnography, plasma-lipid profile, and insulin-resistance [Homeostasis Model Assessment Insulin Resistance (HOMA-IR)] assessments, underwent a sub-maximal progressive treadmill exercise (10 min at 30 and 50%, and 20 min at 75% of Vo2 max), allowing for maximal fat-oxidation rate and blood-oxidative stress determinations. They were compared with 15 healthy control participants (C). Results Vo2 max of DS participants was lower than that of C (60.8 ±2.4 versus 44.4 ± 3.3 ml/kg/min; P < 0.001) but was close to the predicted value (95 ±6%). In DS participants, as expected, oxidative stress was greater than in C (+ 15%; P < 0.001) at rest and all through the exercise protocol. Although a greater fat mass (DS: 19.9 ±1.3%; C: 13.5 ±0.9%; P < 0.001), and a lower insulin sensitivity (HOMA-IR in DS: 1.09±0.16; in C: 0.64±0.13; P < 0.05) was observed for DS participants, a metabolic syndrome could not be shown. Maximal fat-oxidation rate was lower in DS participants (394.2 ±69.9 versus 486.1 ±134.8mg/min in C; P < 0.01), but it was in the normal range. Conclusion Despite greater oxidative stress and lower insulin sensitivity, the DS group involved in our study did not display clear metabolic abnormalities. The young age and lifestyle of this group might, partially, have accounted for this apparently healthy metabolic status.

Effects of acute salbutamol inhalation on quadriceps force and fatigability.

INTRODUCTION Oral beta2-agonist administration improves muscle function in persons without asthma. We performed a double-blind, randomized, controlled crossover study to assess whether acute inhaled salbutamol administration improves muscle strength and fatigability in healthy moderately trained subjects. METHODS Quadriceps muscle strength was measured during maximal voluntary contraction (MVC) and femoral nerve magnetic stimulation (potentiated single twitch, TwQpeak) before and after (i) a maximal incremental cycling test (n = 10) and (ii) 50 maximal isometric one-leg extensions (n = 9). Each exercise test was performed on three occasions, after salbutamol (200 and 800 microg) or placebo inhalation. RESULTS Before exercise, treatments had no significant effect on MVC [(placebo) 597 +/- 146 N vs (200 microg) 629 +/- 151 N vs (800 microg) 610 +/- 148 N] and TwQpeak [(placebo) 215 +/- 83 N vs (200 microg) 227 +/- 69 N vs (800 microg) 250 +/- 84 N]. Maximal power during cycling and maximal force during leg extensions did not differ between treatments. Treatments had no effect on MVC and TwQpeak reductions at 30 min [MVC: (placebo) -8 +/- 9% vs (200 microg) -9 +/- 7% vs (800 microg) -8 +/- 5%; TwQpeak: (placebo) -29 +/- 13% vs (200 microg) -23 +/- 15% vs (800 microg) -20 +/- 8%] and 60 min [MVC: (placebo) -12 +/- 17% vs (200 microg) -6 +/- 9% vs (800 microg) -8 +/- 8%; TwQpeak: (placebo) -20 +/- 21% vs (200 microg) -19 +/- 23% vs (800 microg) -8 +/- 7%] after cycling. Similarly, reductions in MVC and TwQpeak were not significantly different between treatments at 30 [MVC: (placebo) -11 +/- 9% vs (200 microg) -12 +/- 7% vs (800 microg) -8+/- 16%; TwQpeak: (placebo) -37 +/- 12% vs (200 microg) -33 +/- 20% vs (800 microg) -32 +/- 16%] and 60 min [MVC: (placebo) -10 +/- 11% vs (200microg) -11 +/- 6% vs (800 microg) -8 +/- 20%; TwQpeak: (placebo) -30 +/- 11% vs (200 microg) -28 +/- 24% vs (800 microg) -27 +/- 15%] after leg extensions. Treatments did not modify maximal voluntary activation at any time of the protocol. CONCLUSION Acute therapeutic or supratherapeutic doses of inhaled salbutamol have no effect on quadriceps strength, fatigue, and recovery in men without asthma.

Effect of salbutamol on neuromuscular function in endurance athletes.

PURPOSE The potential ergogenic effects of therapeutic inhaled salbutamol doses in endurance athletes have been controversially discussed for decades. We hypothesized that salbutamol inhalation may increase peripheral muscle contractility, reduce fatigability, and improve force recovery after a localized exercise in endurance athletes. METHODS Eleven healthy, nonasthmatic male athletes with high aerobic capacities were recruited to be compared in a double-blinded, randomized crossover study of two dose levels of salbutamol (200 and 800 μg) and a placebo administered by inhalation before a quadriceps fatigue test. Subjects performed an incremental exercise protocol consisting in sets of 10 intermittent isometric contractions starting at 20% of maximum voluntary contraction (MVC) with 10% MVC increment until exhaustion. Femoral nerve magnetic stimulation was used during and after MVC to evaluate neuromuscular fatigue after each set, at task failure, and after 10 and 30 min of recovery. RESULTS Initial MVC and evoked muscular responses were not modified with salbutamol (P > 0.05). The total number of submaximal contractions until task failure significantly differed between treatments (placebo, 72 ± 7; 200 µg, 78 ± 8; and 800 µg, 82 ± 7; P < 0.01). MVC and evoked muscular responses were similarly reduced with all treatments during the fatiguing task (all P > 0.05). Voluntary activation was unaffected by the fatiguing task and treatments (P > 0.05). CONCLUSION Supratherapeutic inhaled doses of β2-agonists increased quadriceps endurance during an incremental and localized fatiguing task in healthy endurance-trained athletes without significant effect on neuromuscular fatigue. Further studies are needed to clarify the underlying mechanisms.

Reduced Cardiorespiratory Capacity in Children with Autism Spectrum Disorders

Background—Children with autistic spectrum disorders (ASDs) are frequently hampered by motor impairment. It limits them from regularly practicing physical activities and results in a lower physical fitness even though low cardiorespiratory fitness is one of the most important predictors of all-cause mortality. This study aimed to investigate the cardiorespiratory fitness of boys with ASD compared to typically developed children. Methods—forty male children participated. Twenty were control children (CONT—10.0 ± 1.6 years) and 20 were ASD children (ASD—10.7 ± 1.2 years; intellectual quotient > 70). All participants completed an incremental exercise test on a treadmill. An evaluation of motor characteristics by three tests was conducted (muscular strength; explosive power; flexibility). Assessments of daily physical activity were obtained by questionnaires (PAQ-C) and by actigraphy. Results—in the ASD group, aerobic capacity values (VO2peak), effort duration and maximal speed were significantly lower compared to CONT (p < 0.05). Flexibility, explosive power and muscular strength were significantly lower in ASD compared to CONT (p < 0.05). Similarities between all children were observed for physical activity evaluation by actigraphy and with the PAQ-C. Conclusions—children with ASD had lower cardiorespiratory fitness than CONT despite similar physical activity levels. Our results suggested that the difference may be due to motor discrepancies.

Low Cardiorespiratory Fitness is Partially Linked to Ventilatory Factors in Obese Adolescents.

AIM To examine the role of ventilatory constraint on cardiorespiratory fitness in obese adolescents. METHODS Thirty obese adolescents performed a maximal incremental cycling exercise and were divided into 2 groups based on maximal oxygen uptake (VO2peak): those presenting low (L; n = 15; VO2peak: 72.9 ± 8.6% predicted) or normal (N; n = 15; VO2peak: 113.6 ± 19.2% predicted) cardiorespiratory fitness. Both were compared with a group of healthy controls (C; n = 20; VO2peak: 103.1 ± 11.2% predicted). Ventilatory responses were explored using the flow volume loop method. RESULTS Cardiorespiratory fitness (VO2peak, in % predicted) was lower in L compared with C and N and was moderately associated with the percent predicted forced vital capacity (FVC) (r = .52; p < .05) in L. At peak exercise, end inspiratory point was lower in L compared with N and C (77.4 ± 8.1, 86.4 ± 7.7, and 89.9 ± 7.6% FVC in L, N, and C, respectively; p < .05), suggesting an increased risk of ventilatory constraint in L, although at peak exercise this difference could be attributed to the lower maximal ventilation in L. CONCLUSION Forced vital capacity and ventilatory strategy to incremental exercise slightly differed between N and L. These results suggest a modest participation of ventilatory factors to exercise intolerance.

L’analyse des perturbations globales du métabolisme d’origine endocrinienne et son application au dépistage du dopage : quel potentiel, quel avenir ?

Resume Les limites actuelles de la detection des pratiques dopantes en competition sont patentes, meme si la puissance analytique deployee est sans commune mesure avec ce qui existait il y a encore quelques annees. C’est qu’en fait certains des principes sur lesquels elle repose sont pris en defaut, le principal etant l’absolue necessite d’apporter la preuve analytique de la fraude. Le recours a des methodes indirectes permettrait de reunir un faisceau de presomptions suffisantes qui orienteraient ainsi plus efficacement la recherche de ces preuves. La methode exposee s’appuie sur l’exploration a haut debit du metabolisme des individus, methode aussi appelee metabonomique, qui a demontre dans le cadre de l’utilisation de substances anabolisantes en elevage tout son potentiel, tant dans le reperage des situations de traitement aux anabolisants que dans l’interpretation fonctionnelle des « mouvements metaboliques » operes en reponse a ces traitements. La transposition au domaine sportif realisee dans le cadre du suivi medical longitudinal et les limites qui peuvent apparaitre dans ce contexte sont evoquees a la lumiere des tout premiers resultats obtenus dans le cadre du suivi d’une cohorte de cyclistes.